Sorrento In-Licenses Four China Biobetter/Biosimilars

Sorrento Therapeutics of San Diego in-licensed four monoclonal antibodies from Mabtech Limited, a holding company for China mAb biopharmas. All four of the mAbs have completed Phase III trials in China; two of them have filed for marketing approval. Sorrento will have rights to the mAbs in the US, Europe and Japan. Mabtech is owned by CDH Investments, an Asian private equity fund with more than $10 billion under management. No financials details were disclosed, nor did the release identify the companies that developed the molecules. More details.... Stock Symbol: (NDNQ: SRNE) Share this with colleagues: // //